SPRY - ARS Pharmaceuticals, Inc.
IEX Last Trade
10.78
0.100 0.928%
Share volume: 75,778
Last Updated: Fri 27 Dec 2024 08:30:40 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$10.68
0.10
0.94%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-02 | 2023-03-23 | 2023-05-15 | 2023-08-10 | 2023-11-09 | 2024-03-21 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 293.999 M | 271.064 M | 281.435 M | 271.192 M | 258.752 M | 248.556 M | 233.188 M | 227.583 M | |
| Current Assets | 263.129 M | 270.799 M | 277.700 M | 267.350 M | 255.034 M | 244.466 M | 231.726 M | 226.241 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.154 M | 4.175 M | 3.319 M | 2.801 M | 2.826 M | 2.564 M | 3.366 M | 2.609 M | |
| Short Term Investments | 5.154 M | 4.175 M | 3.319 M | 2.801 M | 2.826 M | 2.564 M | 3.366 M | 2.609 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 257.975 M | 266.624 M | 274.381 M | 264.549 M | 252.208 M | 241.902 M | 228.360 M | 223.632 M | |
| Total Non-current Assets | 30.870 M | 265.000 K | 3.735 M | 3.842 M | 3.718 M | 4.090 M | 1.462 M | 1.342 M | |
| Property Plant Equipment | 2.485 M | 15.000 K | 329.000 K | 584.000 K | 594.000 K | 617.000 K | 574.000 K | 616.000 K | |
| Other Assets | 3.917 M | 0.000 | 3.406 M | 3.258 M | 3.124 M | 3.473 M | 888.000 K | 726.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 293.999 M | 271.064 M | 281.435 M | 271.192 M | 258.752 M | 248.556 M | 233.188 M | 227.583 M | |
| Total liabilities | 15.208 M | 3.990 M | 8.549 M | 10.037 M | 10.200 M | 11.272 M | 2.428 M | 3.715 M | |
| Total current liabilities | 11.143 M | 3.990 M | 5.444 M | 9.838 M | 10.054 M | 11.180 M | 2.391 M | 3.715 M | |
| Accounts Payable | 2.114 M | 126.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 2.854 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 881.000 K | 215.000 K | 230.000 K | 232.000 K | 233.000 K | 235.000 K | 237.000 K | 217.000 K | |
| Long term debt | 4.065 M | 0.000 | 251.000 K | 199.000 K | 146.000 K | 92.000 K | 37.000 K | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 2.854 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 278.791 M | 267.074 M | 272.886 M | 261.155 M | 248.552 M | 237.284 M | 230.760 M | 223.868 M | |
| Common stock | 35.126 M | 35.458 M | 54.126 M | 94.227 M | 94.911 M | 95.577 M | 96.146 M | 96.486 M | |
| Retained earnings | -230.272 M | -248.136 M | -76.938 M | -91.899 M | -109.269 M | -124.135 M | -131.303 M | -141.595 M |